Financial Performance - The company's operating revenue for the first half of 2021 was CNY 2,143,203,846.80, representing a 21.03% increase compared to CNY 1,770,808,591.63 in the same period last year[29]. - The net profit attributable to shareholders of the listed company reached CNY 274,040,318.92, up 33.47% from CNY 205,317,915.18 in the previous year[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 270,554,642.01, reflecting a 37.11% increase from CNY 197,328,956.79 year-on-year[29]. - The basic earnings per share increased to CNY 0.28, a rise of 27.27% compared to CNY 0.22 in the same period last year[29]. - The total assets at the end of the reporting period were CNY 6,887,522,958.74, showing a 0.72% increase from CNY 6,838,231,066.49 at the end of the previous year[29]. - The net assets attributable to shareholders of the listed company increased by 2.35% to CNY 4,549,287,414.08 from CNY 4,444,931,882.40 at the end of the previous year[29]. - The net cash flow from operating activities was CNY 234,107,076.76, which is a decrease of 4.14% compared to CNY 244,208,628.76 in the same period last year[29]. - The weighted average return on net assets was 6.06%, down from 6.81% in the previous year, indicating a decrease of 0.75%[29]. Revenue Breakdown - Sales revenue from formulations was 1.162 billion yuan, a 31% increase, with self-operated product sales reaching 1.134 billion yuan, up 38%[40]. - The sales revenue of raw materials and intermediates was 964 million yuan, a 9.5% increase, with self-operated raw material sales at 595 million yuan, up 16%[40]. - Domestic sales accounted for ¥1,527,052,896.59, which is 71.25% of total revenue, showing a growth of 29.09% compared to the previous year[69]. - The revenue from anesthetics and muscle relaxants surged by 68.86% to ¥393,975,393.22, contributing 18.38% to total revenue[69]. Research and Development - Research and development expenses increased by 30.48% to CNY 99,242,121.29, up from CNY 76,058,999.29 in the previous year[66]. - The company is actively advancing product research and development, with several new drug applications and consistency evaluations in progress, including Dexamethasone sodium phosphate injection[51]. - The company has successfully passed consistency evaluations for several products, including Finasteride tablets and Mifepristone tablets, enhancing its product portfolio[51]. - The company has submitted applications for 22 consistency evaluation products, with 8 submitted and 4 passed, and 18 new generic products, with 5 submitted[54]. Market Position and Strategy - The company focuses on the steroid drug sector, emphasizing the integration of raw materials and formulations to enhance competitiveness[45]. - The company is actively expanding its international market presence, with steady progress in developing raw material customers[45]. - The company is positioned in a stable competitive landscape within the steroid hormone industry, maintaining a strong market share in the first tier of the industry[49]. - The steroid drug industry in China accounts for approximately one-third of the global production of steroid raw materials, indicating a significant production capacity[47]. Risks and Challenges - The company has identified several risks including industry policy changes, drug price reduction risks, and R&D risks, which are detailed in the management discussion section[6]. - The company faces risks from industry policy changes and potential drug price reductions due to stricter regulations and reforms in the healthcare system[97]. - Quality control risks are heightened due to new regulations and standards impacting the entire lifecycle of drug development and production[98]. - R&D risks are present due to high investment and long cycles associated with new drug development, necessitating a focus on core therapeutic areas[98]. - Environmental risks are increasing due to stricter pollution control regulations, prompting the company to enhance its environmental protection measures[99]. Environmental Responsibility - The company reported a total COD discharge of 1.01 tons and ammonia nitrogen discharge of 0.27 tons from its Jiangnan plant, adhering to environmental standards[110]. - The company has a pollution prevention facility in operation, ensuring compliance with environmental regulations[113]. - The company achieved a stable operation rate of over 99% for its environmental protection facilities during the reporting period[114]. - The company has established a complete internal control system and an investor interaction platform to ensure fair treatment of all shareholders[120]. Shareholder Information - The total number of shareholders at the end of the reporting period was 35,247, with a significant shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holding 21.55% of shares, totaling 213,221,808 shares[190]. - The total number of shares is 989,204,866, with 97.30% being unrestricted shares[182]. - The company has a total of 4,379,562 shares subscribed by Huatai Asset Management Co., Ltd. and 4,014,598 shares by China Merchants Fund Management Co., Ltd., both of which have also completed their lock-up commitments[135][138]. - The report indicates that the company has not experienced any significant changes in shareholder structure during the reporting period[190].

证券代码：002332 证券简称：仙琚制药 公告编号：2021-026 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2021年4月28日发布了《2020 年年度报告》，为便于广大投资者深入全面地了解公司情况，公司将举办投资者接 待日活动，现将有关事项公告如下： 一、活动时间 2021年5月19日（星期三）上午9:30-11:30。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2021年5月17-18日（上午8:30-11:00，下午14:00-16:00）与公 司董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和 安排。 联系人：沈旭红 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长兼总经理张宇松先生、财务总监王瑶华女士、董事会秘书张王伟先生（如 有特殊情况，参与人员会有调整）。 五、注意事项 1、来访个人投资者请携带个人身份 ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2020, representing a year-on-year growth of 15%[7]. - The net profit attributable to shareholders was 250 million RMB, an increase of 20% compared to the previous year[7]. - The company's operating revenue for 2020 was ¥4,018,872,772.40, an increase of 8.37% compared to ¥3,708,545,530.97 in 2019[27]. - Net profit attributable to shareholders for 2020 was ¥504,509,427.41, representing a growth of 22.94% from ¥410,368,585.97 in 2019[27]. - The total profit reached 621.25 million yuan, up 17.82% year-on-year, while net profit attributable to shareholders was 504.51 million yuan, reflecting a 22.94% increase[65]. - The company achieved a revenue of 4,018.87 million CNY, representing a year-on-year growth of 8.37%[44]. - The net cash flow from operating activities increased by 51.83% to ¥789,233,376.74 from ¥519,805,113.67 in 2019[27]. - The company reported a total sales volume of 400,196.45 million yuan in 2020, an increase of 8.27% from 2019[82]. Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares, based on a total share capital of 989,204,866 shares as of December 31, 2020[7]. - In 2020, the company distributed cash dividends totaling ¥148,380,729.90, which represents 29.41% of the net profit attributable to shareholders of the listed company[164]. - The net profit attributable to shareholders for 2020 was ¥504,509,427.41, with a profit distribution base of 989,204,866 shares, resulting in a cash dividend of ¥1.5 per 10 shares[167]. - The total distributable profit for the year was ¥931,501,460.58, with cash dividends accounting for 100% of the profit distribution[167]. - The company executed a cash dividend of 1 CNY per 10 shares for the 2019 fiscal year, amounting to approximately 91.62 million CNY[163]. - The company issued a cash dividend of 0.65 CNY per 10 shares for the 2018 fiscal year, totaling approximately 59.55 million CNY[163]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its R&D capabilities to drive future growth[7]. - New product launches are expected to contribute significantly to revenue in the upcoming fiscal year, with a target of introducing at least 5 new drugs[7]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[7]. - The company aims to achieve a revenue growth target of 20% for the next fiscal year, driven by new product introductions and market expansion strategies[7]. - The company is actively expanding into international markets, enhancing its market share in the global steroid industry[44]. - The company aims to enhance market share in the raw material drug sales by coordinating various departments and responding quickly to market demands, focusing on high-end market expansion in Latin America, the Middle East, and Russia[142]. Research and Development - The company is investing heavily in technology development, with a budget allocation of 100 million RMB for R&D in 2021[7]. - The company received 7 national invention patents during the reporting period, bringing the total to 42 authorized patents, enhancing its R&D capabilities[58]. - Research and development investment amounted to ¥208,385,907.97 in 2020, representing a 1.89% increase from ¥204,521,925.83 in 2019[101]. - The number of R&D personnel increased to 448, a 4.19% rise from 430 in the previous year[101]. - Continuous improvement of R&D capabilities is emphasized, with a focus on consistency evaluation and innovative R&D projects, aiming to establish a stable performance in the production line and develop a steroid drug API platform[143]. Risk Management - The company has identified key risks including industry policy changes, drug price reductions, and R&D risks, which may impact future performance[7]. - The company is addressing risks related to industry policy changes and drug price reductions by closely monitoring industry trends and enhancing innovative product development[149]. - The company faces quality control risks due to new regulations and standards, necessitating improved coordination among research, production, and quality departments[150]. - The company recognizes the risk of talent shortages as it expands and integrates acquisitions, emphasizing the need for skilled professionals with international perspectives[151]. Operational Efficiency - The company has a strong emphasis on internal management and cost control, resulting in significant operational efficiency improvements[44]. - The company is committed to compliance production and comprehensive cost control, establishing a new responsibility assessment system to enhance operational efficiency and production capacity[144]. - Quality management systems are being enhanced to meet international standards, with ongoing efforts in the registration of international raw material drug varieties and compliance with GMP standards[145]. - The implementation of an integrated management system through the Kingdee ERP project aims to optimize business processes and improve operational efficiency across various departments[146]. Subsidiaries and Investments - The company established two new subsidiaries, Jiaxing Pharmaceutical Company and Hangzhou Technology Innovation Company, with an investment of 3.5 million yuan each, acquiring a 70% stake in both[192]. - The subsidiary Taizhou Xianju Pharmaceutical Co., Ltd. reported a net profit of ¥76,404,900, contributing over 10% to the company's net profit[127]. - The company has invested in several overseas subsidiaries, with total foreign equity assets amounting to CNY 30.99 million for Newchem and CNY 28.23 million for Effechem, contributing positively to revenue[53]. Compliance and Governance - The company has committed to strict adherence to share lock-up agreements for its major shareholders following the non-public issuance of A-shares[171]. - The company has a commitment from its actual controller and major shareholders to fulfill their obligations during the reporting period[168]. - The company has not faced any major litigation or arbitration matters during the reporting period[198]. - The company has maintained a continuous audit service with Tianjian Accounting Firm for 20 years, with an audit fee of 1.85 million yuan for the current period[193].

Financial Performance - The company's revenue for Q1 2021 reached ¥1,001,363,720.40, representing a 34.47% increase compared to ¥744,695,096.98 in the same period last year[10] - Net profit attributable to shareholders was ¥110,602,233.70, a 64.21% increase from ¥67,354,593.92 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥108,605,653.74, up 71.59% from ¥63,293,446.50 in the previous year[10] - Basic earnings per share increased to ¥0.11, reflecting a 57.14% rise from ¥0.07 in the same period last year[10] - Operating revenue increased by 34.47% year-on-year, an increase of 256.67 million yuan, primarily due to increased sales[21] - Net profit for the current period was ¥112,589,627.22, compared to ¥62,519,729.43 in the previous period, indicating an increase of approximately 80.3%[62] - The company reported a total profit of ¥142,095,156.42 for the current period, compared to ¥73,874,203.54 in the previous period, indicating an increase of approximately 92.5%[62] - Total comprehensive income for the period was ¥89,573,617.31, up from ¥60,492,671.74, reflecting an increase of approximately 48.1%[69] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,888,947,058.02, a slight increase of 0.74% from ¥6,838,231,066.49 at the end of the previous year[10] - The net assets attributable to shareholders rose to ¥4,535,757,745.54, marking a 2.04% increase from ¥4,444,931,882.40 at the end of the last year[10] - Current liabilities totaled ¥1,598,077,862.09, slightly down from ¥1,618,839,755.19, a decrease of about 1.49%[45] - Non-current liabilities amounted to ¥637,980,586.52, a marginal increase from ¥637,041,731.85, reflecting a growth of approximately 0.15%[45] - Total liabilities decreased to ¥2,236,058,448.61 from ¥2,255,881,487.04, showing a decline of about 0.88%[45] - Owner's equity increased to ¥4,652,888,609.41 from ¥4,582,349,579.45, representing a growth of approximately 1.53%[48] - Total liabilities amounted to ¥976,471,430.37, an increase from ¥947,841,487.03, showing a rise of about 3.3%[55] - Total equity increased to ¥4,140,293,947.62 from ¥4,050,720,330.31, reflecting a growth of approximately 2.2%[55] Cash Flow - The net cash flow from operating activities was ¥64,571,088.88, down 32.16% from ¥95,178,224.07 in the same period last year[10] - Cash flow from operating activities was ¥64,571,088.88, down from ¥95,178,224.07, indicating a decrease of about 32.1%[73] - Cash outflow from investment activities totaled CNY 160,507,277.41, significantly higher than CNY 29,338,917.21 in the previous period[80] - Net cash flow from investment activities was negative at CNY -123,787,277.41, compared to CNY -22,259,271.19 in the previous period[80] - Cash inflow from financing activities was CNY 219,786,706.25, down from CNY 271,900,000.00 in the previous period[80] - Net cash flow from financing activities decreased to CNY 62,102,934.96 from CNY 82,268,317.24, a decline of 24.5%[80] - The ending balance of cash and cash equivalents was CNY 765,605,482.12, compared to CNY 554,307,518.79 in the previous period, reflecting an increase of 38.1%[80] Research and Development - R&D expenses increased by 83.49% year-on-year, an increase of 23.59 million yuan, mainly due to increased R&D expenditures[21] - Research and development expenses rose to ¥51,854,252.28 from ¥28,260,023.13, representing an increase of about 83.5%[60] - Research and development expenses increased to ¥34,698,246.73 from ¥21,096,087.02, reflecting a growth of approximately 64.5%[66] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,308[14] - The largest shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., held 21.55% of the shares[14] - The company has raised a total of 987.36 million yuan from a private placement of shares, with 29.24 million yuan already invested in projects as of March 31, 2021[28] Other Financial Metrics - Cash received from other operating activities increased by 1112.71% year-on-year, an increase of 34.60 million yuan, mainly due to the recovery of commercial bill deposits[22] - Cash paid for purchasing goods and accepting services increased by 68.71% year-on-year, an increase of 121.43 million yuan, mainly due to increased cash payments for purchases[22] - Financial expenses decreased by 39% year-on-year, a reduction of 5.03 million yuan, mainly due to decreased interest expenses from reduced loans[21] - Other income decreased by 56.6% year-on-year, a reduction of 3.77 million yuan, mainly due to a decrease in government subsidies received[21] - Cash paid for dividends and interest increased by 225.1% year-on-year, an increase of 19.54 million yuan, mainly due to increased dividends distributed to minority shareholders[22]

Financial Performance - Operating revenue for the period was ¥1,162,850,644.68, representing a year-on-year growth of 27.88%[10] - Net profit attributable to shareholders was ¥153,139,417.63, up 30.76% from the same period last year[10] - The total net profit for the year-to-date period reached ¥358,457,332.81, marking a 23.26% increase compared to the same period last year[10] - Basic earnings per share for the period were ¥0.17, reflecting a growth of 30.77% compared to the previous year[10] - The company reported a net profit excluding non-recurring gains and losses of ¥146,763,103.65, which is a 22.44% increase year-on-year[10] - The company reported a net profit of CNY 1,248,481,385.84, up from CNY 981,645,269.63, which is an increase of approximately 27.2%[47] - Net profit for Q3 2020 was CNY 164,432,879.79, representing a 26% increase from CNY 130,796,187.47 in Q3 2019[60] - The net profit for the current period is CNY 378,922,638.64, compared to CNY 326,346,375.05 in the previous period, reflecting an increase of about 16.06%[75] - The company’s net profit attributable to the parent company is CNY 358,457,332.81, compared to CNY 290,822,049.48 in the previous period, reflecting an increase of approximately 23.29%[77] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,328,685,028.77, an increase of 8.66% compared to the end of the previous year[10] - The company’s total equity attributable to shareholders was ¥3,211,084,810.59, up 9.16% from the previous year[10] - Current liabilities increased to CNY 2,045,695,738.29 from CNY 1,747,205,179.39, representing a rise of about 17.1%[44] - The total liabilities reached CNY 2,984,506,353.88, compared to CNY 2,765,742,131.88, indicating an increase of approximately 7.9%[44] - The total equity attributable to shareholders increased to CNY 3,211,084,810.59 from CNY 2,941,524,857.14, reflecting a growth of about 9.2%[47] - The total liabilities rose to CNY 1,410,343,380.05, compared to CNY 1,159,281,844.07 in the previous year, highlighting increased financial obligations[54] - Total current liabilities stood at CNY 1,747,205,179.39, consistent with the previous period[108] - Total liabilities amounted to CNY 2,765,742,131.88, with non-current liabilities at CNY 1,018,536,952.49[112] Cash Flow - The net cash flow from operating activities was ¥227,652,709.31, a significant increase of 319.56% year-on-year[10] - Cash received from other operating activities increased by 135.54% year-on-year, an increase of 99.7396 million yuan, mainly due to an increase in the recovery of commercial bill deposits[21] - Operating cash inflow for the current period reached CNY 1,204,524,411.77, an increase of 26% compared to CNY 956,511,121.88 in the previous period[96] - Net cash flow from operating activities was CNY 311,076,475.48, up 69% from CNY 183,888,170.93 year-over-year[99] - Cash inflow from financing activities was CNY 651,900,000.00, compared to CNY 612,900,000.00 in the previous period, with a net cash flow of CNY 34,202,404.36[101] Expenses - Total operating costs amounted to CNY 959,595,674.74, up from CNY 754,198,140.59, reflecting a significant increase in operational expenses[57] - Research and development expenses increased to CNY 56,953,663.68, compared to CNY 44,274,125.62 in the previous year, indicating a focus on innovation[57] - The financial expenses for the quarter were CNY 17,961,240.56, an increase from CNY 12,105,359.96, indicating higher borrowing costs[57] - The total operating expenses increased to ¥1,041,652,000.00, up from ¥848,000,000.00 in the previous period, indicating a rise of 23.0%[81] Investment Activities - Investment income decreased by 81.68% year-on-year, a decrease of 17.0816 million yuan, mainly due to the disposal of subsidiaries last year[21] - The investment income for the current period is CNY 3,830,399.88, down from CNY 20,911,953.31 in the previous period, indicating a decrease of about 81.69%[75] - The company’s investment activities generated a net cash outflow of ¥85,412,535.95, an improvement from a net outflow of ¥233,697,979.17 in the previous period[90] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[60]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,770,808,591.63, a decrease of 4.78% compared to CNY 1,859,750,579.21 in the same period last year[27]. - Net profit attributable to shareholders of the listed company reached CNY 205,317,915.18, an increase of 18.20% from CNY 173,705,966.92 year-on-year[27]. - The net profit after deducting non-recurring gains and losses was CNY 197,328,956.79, reflecting a growth of 20.77% compared to CNY 163,394,977.46 in the previous year[27]. - The net cash flow from operating activities was CNY 244,208,628.76, down 29.97% from CNY 348,701,041.02 in the same period last year[27]. - Basic earnings per share increased to CNY 0.22, up 15.79% from CNY 0.19 in the previous year[27]. - The company achieved operating revenue of 1,770.81 million yuan, a decrease of 4.78% year-on-year[41]. - The net profit attributable to shareholders was 205.32 million yuan, an increase of 18.20% year-on-year[41]. - The company reported a non-recurring profit and loss total of 7,988,958.39 yuan[34]. - The company’s R&D investment increased by 16.08% to ¥76,058,999.29 from ¥65,523,586.04 year-on-year[67]. - The company achieved a gross margin of 56.21% in the pharmaceutical sector, down 3.29% from the previous year[73]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,018,606,723.52, representing a 3.34% increase from CNY 5,824,345,547.49 at the end of the previous year[27]. - Net assets attributable to shareholders of the listed company were CNY 3,060,378,186.30, an increase of 4.04% from CNY 2,941,524,857.14 at the end of the previous year[27]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,022,410,393.59, accounting for 16.99% of total assets, a decrease of 1.13% compared to the previous year[77]. - Accounts receivable totaled ¥847,207,438.11, representing 14.08% of total assets, down by 1.75% year-on-year[77]. - Fixed assets increased to ¥1,570,189,530.63, making up 26.09% of total assets, an increase of 7.24% from the previous year[77]. - Short-term borrowings were ¥631,540,778.27, which is 10.49% of total assets, a decrease of 1.20% compared to the previous year[77]. - Long-term borrowings decreased to ¥781,693,098.89, accounting for 12.99% of total assets, down by 6.05% year-on-year[77]. - Current liabilities rose to approximately $1.99 billion, compared to $1.75 billion, marking an increase of about 14.1%[197]. - Non-current liabilities decreased to approximately $844.28 million from $1.02 billion, a reduction of about 17.1%[197]. - Total liabilities increased to approximately $2.84 billion from $2.77 billion, reflecting a growth of about 2.5%[197]. Business Strategy and Operations - The company plans not to distribute cash dividends or issue bonus shares[8]. - The company plans to focus on the steroid hormone segment and enhance its integrated development of raw materials and formulations[41]. - The company aims to optimize its marketing system and expand in core therapeutic areas while increasing international registrations[41]. - The company will introduce new products by learning from advanced production management experiences[41]. - The respiratory formulation products maintained good growth, and the export of raw materials increased rapidly[41]. - The company has established stable business relationships with over 100 domestic steroid drug manufacturers, maintaining a stable market share[48]. - The company has completed the construction of three core manufacturing platforms in China and two standardized raw material drug factories in Italy[49]. - The company has optimized its sales model to enhance sales capabilities, focusing on academic promotion and market strategies[61]. - The company’s terminal marketing network covers over 7,000 hospitals and 60,000 pharmacies nationwide, providing a solid foundation for future product launches[48]. Risks and Challenges - The company faces various risks including industry policy changes, raw material price fluctuations, and R&D risks[7]. - The company faces risks related to industry policy changes and drug price reductions, which could significantly impact production, circulation, and usage of drugs[95]. - The company is focused on enhancing its innovation system and optimizing resource allocation to mitigate drug price reduction risks[95]. - The COVID-19 pandemic has significantly impacted the company's operational efficiency, particularly in project implementation and business promotion[99]. - The company anticipates a potential slowdown or decline in revenue growth if the pandemic is not effectively controlled in the short term[99]. Compliance and Governance - The company has not engaged in any major litigation or arbitration matters during the reporting period[108]. - The company has not conducted any significant related party transactions during the reporting period[112]. - The company has not implemented any employee incentive plans during the reporting period[111]. - The company has maintained compliance with court judgments and has no significant overdue debts[110]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[115]. - The financial report for the first half of 2020 was not audited[189]. - The company has not reported any public bonds that are due or unable to be fully repaid as of the report date[186]. Environmental Compliance - The company operates one continuous discharge point for pollutants, with a total COD discharge of 9.18 tons and nitrogen discharge of 1.17 tons[134]. - The company’s discharge concentrations for COD and ammonia nitrogen are within the regulatory standards, with COD at 104.72 mg/L and ammonia nitrogen at 13.39 mg/L[134]. - The company has established and operated pollution prevention facilities, ensuring compliance with environmental standards[137]. - The company reported a stable operation of environmental facilities with an overall stable operation rate exceeding 99% during the reporting period[141]. - The company’s wastewater discharge complies with the "Comprehensive Discharge Standard for Wastewater" GB8978-1996, with COD limits of ≤480 mg/L for certain plants and ≤500 mg/L for others[141]. - The company has implemented a daily monitoring scheme for wastewater discharge to ensure compliance with standards[141]. - The company’s noise emissions comply with the GB12348-2008 standard, with daytime limits of ≤65 dB(A) and nighttime limits of ≤55 dB(A)[141]. Shareholder Information - The company’s major shareholder, Xianju County State-owned Assets Investment Group Co., Ltd., holds 21.55% of the shares, totaling 197,488,304 shares[156]. - The company reported a decrease in limited shares from 12,202,225 to 11,018,875, representing a reduction of approximately 9.7%[152]. - The total number of shares increased from 916,212,166 to 916,212,166, with no change in total shares[152]. - The top ten shareholders held a total of 197,488,304 shares, with the largest shareholder being Xianju County State-owned Assets Investment Group Co., Ltd.[162]. - The company did not engage in any repurchase transactions among its top ten shareholders during the reporting period[168].

证券代码：002332 证券简称：仙琚制药 公告编号：2020-024 浙江仙琚制药股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，浙江仙琚制药股份有限公司（以下简称 "公司"）将参加由中国证监会浙江证监局指导、浙江上市公司协会与深圳市全 景网络有限公司共同举办的"凝心聚力 共克时艰"辖区上市公司投资者网上集 体接待日主题活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net）参 与公司本次投资者网上接待日活动。网上互动交流时间为 2020 年 5 月 15 日（星 期五）下午 15:00-17:00。 届时公司董事长张宇松先生、财务总监王瑶华女士、董事会秘书张王伟先生 及相关工作人员将采用网络远程方式，与投资者就公司治理、发展战略、经营状 况、可持续发展等投资者所关心的问题进行交流。（如有特殊情况，参与人员会 有调整） 欢迎广大投资者 ...

Financial Performance - The company's revenue for Q1 2020 was ¥744,695,096.98, a decrease of 10.89% compared to ¥835,738,416.97 in the same period last year[10] - Net profit attributable to shareholders was ¥67,354,593.92, representing an increase of 16.11% from ¥58,010,342.60 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥63,293,446.50, up 12.50% from ¥56,262,217.21 in the previous year[10] - The basic earnings per share increased to ¥0.07, a rise of 16.67% compared to ¥0.06 in the same period last year[10] - The company's total operating costs decreased to 675,384,458.77 CNY from 740,804,636.07 CNY, a reduction of about 8.8%[59] - The net profit for the current period is 62,519,729.43 CNY, down from 73,803,935.73 CNY in the previous period, indicating a decrease of about 15.5%[59] - The total comprehensive income for the current period is 62,410,867.55 CNY, compared to 71,657,483.74 CNY in the previous period, a decrease of about 12.4%[62] - The total comprehensive income amounted to ¥60,492,671.74, an increase from ¥23,972,321.17 in the previous period[69] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,958,227,827.34, reflecting a growth of 2.30% from ¥5,824,345,547.49 at the end of the previous year[10] - Total assets as of March 31, 2020, amounted to 5.96 billion yuan, an increase from 5.82 billion yuan at the end of 2019[37] - Total liabilities rose to CNY 1,223,463,237.20, up from CNY 1,159,281,844.07, indicating an increase of about 5.5%[53] - The company's total equity increased to CNY 2,776,799,679.71 from CNY 2,716,307,007.97, representing a growth of approximately 2.2%[53] - The total liabilities to equity ratio stands at approximately 44.1%, indicating a stable leverage position for the company[53] Cash Flow - The net cash flow from operating activities was ¥95,178,224.07, a decrease of 7.15% from ¥102,508,038.15 in the same period last year[10] - Cash inflow from operating activities totaled ¥742,048,619.04, down from ¥794,392,215.40 in the previous period, representing a decrease of approximately 6.6%[70] - Cash outflow from operating activities was ¥646,870,394.97, compared to ¥691,884,177.25 previously, indicating a decrease of about 6.5%[73] - Net cash flow from investing activities was -¥7,070,879.93, an improvement from -¥20,865,453.73 in the previous period[73] - Net cash flow from financing activities was ¥82,715,162.42, compared to -¥4,530,098.04 previously, showing a significant turnaround[76] - The cash and cash equivalents at the end of the period reached ¥878,050,916.64, up from ¥630,201,554.26, an increase of approximately 39.2%[76] - The company reported a net increase in cash and cash equivalents of ¥175,496,482.51, compared to ¥69,245,913.46 in the previous period, reflecting a growth of about 153.5%[76] Shareholder Information - The total number of shareholders at the end of the reporting period was 33,067, with the largest shareholder holding 21.55% of the shares[14] - The net assets attributable to shareholders increased to ¥3,008,770,589.18, up 2.29% from ¥2,941,524,857.14 at the end of the previous year[10] Receivables and Payables - Accounts receivable decreased by 52.07% compared to the beginning of the year, a reduction of 2.08 million yuan, mainly due to the collection of matured notes[22] - Financing receivables decreased by 35.24% compared to the beginning of the year, a reduction of 97.88 million yuan, primarily due to the payment of purchase amounts through note transfers[22] - Prepayments increased by 61.03% compared to the beginning of the year, an increase of 20.74 million yuan, mainly due to an increase in prepayments as per contracts[22] - Other receivables increased by 30% compared to the beginning of the year, an increase of 9.25 million yuan, mainly due to an increase in other temporary payments[22] - Other current assets decreased by 55.51% compared to the beginning of the year, a reduction of 30.59 million yuan, mainly due to a decrease in retained tax amounts and the maturity of structured deposits[22] Expenses - Financial expenses decreased by 48.53% compared to the same period last year, a reduction of 12.17 million yuan, mainly due to an increase in exchange gains[23] - Other income increased by 83.41% compared to the same period last year, an increase of 3.03 million yuan, mainly due to an increase in government subsidies received[23] - Research and development expenses increased to 28,260,023.13 CNY from 22,398,036.17 CNY, reflecting a rise of approximately 26.5%[59] - The company's sales expenses decreased to 207,988,438.87 CNY from 251,307,964.61 CNY, a reduction of approximately 17.2%[59] - The tax expenses for the current period are 4,826,080.73 CNY, down from 7,688,109.88 CNY, indicating a decrease of about 37.5%[59] Other Information - The company received government subsidies amounting to ¥6,656,275.45 during the reporting period[10] - The first quarter report for 2020 was not audited, which may affect the reliability of the financial data presented[93] - The company is implementing new revenue and lease standards starting in 2020, which may impact future financial reporting[93]

Financial Performance - The company's operating revenue for 2019 was approximately ¥3.71 billion, representing a 2.40% increase compared to the previous year[21]. - The net profit attributable to shareholders for 2019 was approximately ¥410.37 million, a significant increase of 36.17% year-over-year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥378.11 million, reflecting a 33.90% increase from the previous year[21]. - The net cash flow from operating activities reached approximately ¥519.81 million, marking a substantial increase of 168.96% compared to the previous year[21]. - The total assets at the end of 2019 amounted to approximately ¥5.82 billion, which is a 7.00% increase from the end of 2018[23]. - The net assets attributable to shareholders at the end of 2019 were approximately ¥2.94 billion, showing an 11.77% increase year-over-year[23]. - The basic earnings per share for 2019 were ¥0.45, up 36.36% from ¥0.33 in 2018[21]. - The diluted earnings per share also stood at ¥0.45, reflecting the same percentage increase as the basic earnings per share[21]. - The weighted average return on equity for 2019 was 14.78%, an increase from 12.05% in 2018[21]. - The company reported a total of ¥32.26 million in non-recurring gains for 2019, compared to ¥18.99 million in 2018[30]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 1 RMB per 10 shares (including tax) to all shareholders, based on a total of 916,212,160 shares[5]. - The cash dividend for 2019 represents 22.33% of the net profit attributable to shareholders, which is 410,368,585.97 yuan[129]. - The total distributable profit for the year is 716,700,923.75 yuan, after accounting for the previous year's dividend distribution[132]. - The cash dividend payout ratio for the last three years has been 22.33% in 2019, 19.76% in 2018, and 26.60% in 2017[129]. - The company has maintained a consistent dividend policy over the past three years, with increasing cash dividends each year[128]. Market and Industry Position - The pharmaceutical industry in China is experiencing a robust growth trend, with a revenue increase of 7.4% in 2019, outpacing the overall industrial growth rate[35]. - The global pharmaceutical expenditure is approaching $1.3 trillion, with China being the second-largest market, projected to exceed $1.5 trillion by 2023[35]. - The steroid drug industry is characterized by high entry barriers and significant technical challenges, with the company positioned among the leading manufacturers in China[39]. - The company maintains a strong market share in the steroid hormone sector, ranking in the first tier of the industry[39]. - The company is actively expanding its international market presence, enhancing its competitive advantage in the global hormone industry[35]. Research and Development - The company is focused on R&D and aims to complete the consistency evaluation of generic drug quality and efficacy on schedule[5]. - The company emphasizes the importance of talent acquisition and retention to mitigate risks associated with R&D and operational efficiency[5]. - The company holds 35 authorized invention patents, showcasing its strong R&D capabilities[47]. - Research and development expenses increased by 43.17% to ¥204,521,925.83 compared to ¥142,852,404.83 in the previous year[79]. - The number of R&D personnel rose by 58.09% to 430 in 2019, increasing the proportion of R&D staff to 11.65% of the total workforce[90]. - The company is focused on expanding its product portfolio through new drug applications and re-registrations to enhance market presence[81]. Operational Stability and Compliance - The company has not reported any changes in its main business since its listing, indicating stability in operations[20]. - The company operates under strict GMP (Good Manufacturing Practice) standards to ensure product quality[12]. - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[4]. - The company is committed to ensuring compliance with the new drug management laws and enhancing its quality assurance system to align with international standards[116]. Risk Management - The company highlighted risks including industry policy changes, drug price reductions, and raw material price fluctuations, which could impact future performance[5]. - The company acknowledges the high risks associated with new drug development, including long cycles and regulatory scrutiny, and is refining its R&D focus to mitigate these risks[122]. - The company is addressing the risk of fluctuating raw material prices, which could impact product costs, by enhancing its market research and focusing on high-end international registrations[122]. Environmental Responsibility - The company maintains a commitment to environmental protection and sustainable development, ensuring compliance with national environmental regulations and investing in necessary environmental protection facilities[176]. - The company has established wastewater treatment facilities with capacities of 2200 t/d, 400 t/d, 1400 t/d, and 150 t/d across its main plant and subsidiaries, all operating normally during the reporting period[184]. - The total emissions for the main plant and subsidiaries include COD at 433.584 tons, ammonia nitrogen at 31.615 tons, total phosphorus at 7.226 tons, and total nitrogen at 63.231 tons, all within regulatory limits[184]. - The company achieved a stable operation rate of over 99% for its environmental protection facilities, ensuring compliance with pollution discharge standards[184]. Corporate Governance - The company emphasizes the protection of shareholder and creditor rights, ensuring compliance with legal regulations and providing a network voting platform for minority shareholders[172]. - The company has established a comprehensive performance evaluation system and offers career planning and training programs to enhance employee skills and promote mutual growth[174]. - The company has maintained its accounting firm, 天健会计师事务所, for 19 consecutive years, with an audit fee of CNY 1.85 million[145].

证券代码：002332 证券简称：仙琚制药 公告编号：2020-014 浙江仙琚制药股份有限公司 关于举办投资者接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2020年4月25日发布了《2019 年年度报告》，为便于广大投资者深入全面地了解公司情况，公司将举办投资者接 待日活动，现将有关事项公告如下： 一、活动时间 2020年5月19日（星期二）上午9:30-11:30。 二、活动地点 浙江省仙居县福应街道现代工业集聚区丰溪西路15号，公司会议室。 三、预约方式 参与投资者请于2020年5月14-15日（上午8:30-11:00，下午14:00-16:00）与公 司董事会秘书办公室联系，提前预约登记，并同时提供问题提纲，以便接待登记和 安排。 联系人：沈旭红 电话：0576-87731138，传真：0576-87731138。 四、公司参与人员 董事长兼总经理张宇松先生、财务总监王瑶华女士、董事会秘书张王伟先生（如 有特殊情况，参与人员会有调整）。 五、注意事项 1、来访个人投资者请携带个人身份 ...